Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: DaiS who wrote (20830)	4/20/1999 1:55:00 PM
From: VLAD	Respond to of 23519

DaiS, I was wondering if you could call A/Z HQs in London and make contact with their IR department. I would like to know EXACTLY when A/Z plans on launching MUSE. I was told by Vivus "May" but that they did not know when in May. Thanks. VLAD

To: DaiS who wrote (20830)	4/20/1999 2:40:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

DaiS, Back to this study that I noted in an earlier post: auanet.org I asked Vivus a LONG time ago if PDE5 inhibitors could be delivered and absorbed transurethrally. I was told by Nina that she didn't know but that she would have someone in R&D get back to me(they never did). Shortly after we had that fly by night Malaysian company develop that internet site you pointed out which sold their own version of MUSE and a sildenafil product that was delivered transurethrally as is MUSE. Indeed the study was authored by a PC Doherty the same PC Doherty who used to be a VP of Research at Vivus but left back in June of 1998. In fact if you look at the Vivus profile on Yahoo he is still listed as an officer of the company (talk about poor updating): biz.yahoo.com The point is that I like the results they achieved using a combination of Zaprinast(like Viagra a PDE-5 inhibitor) and alprostadil. I believe that Vivus would be wise to obtain the rights to use a PDE-5 inhibitor in a third generation transurethral product. I believe that a product such as Alibra(alprostadil and prazosin) with a PDE-5 inhibitor added could very well be a significant advance for Vivus. You can call it Vivus' own Trimix. And for those who are sensitive to alprostadil they can develop a PDE-5 inhibitor/prazosin product that may be quite effective with fewer side effects. The good thing to know is that PDE-5 inhibitors CAN be absorbed transurethrally and they DO work via the local delivery method. This is great news for us since Vivis holds the transurethral delivery patents.